Skip to main content
Fig. 3 | Journal of Innovation and Entrepreneurship

Fig. 3

From: A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates

Fig. 3

rNPV calculations for the four interventions using indication specific FEC high and low costs and phase specific cumulative progressive success rate. Progressive success rates indicated in Table 5 were used in the rNPV calculations for indication specific low (red line) and indication specific high (blue line) value calculations. a Chemical entity—heart. b Biological—heart. c Chemical entity—diabetes. d Biological—diabetes

Back to article page